Amrubicin for small cell lung cancer – pro

Amrubicin, previously known as SM-5887, is an anthracycline used in the treatment of lung cancer. It is marketed in Japan since 2002 by Sumitomo Pharmaceuticals under the brand name Calsed. Two phase 2 studies of amrubicin in Japanese populations with previously treated SCLC have shown impressive results. Amrubicin has been granted Fast Track product designation by the U.S. Food and Drug Administration (FDA) for the treatment of small cell lung cancer after first-line chemotherapy.
Amrubicin is being studied in clicnal trials and there are currenlty seven such trials ongoing (

Participate in our Forums

To ask questions or participate in a discussion, please visit our Forums. You must LOGIN to participate.

Help Us Help Others

You can become a Site Sponsor. Or you may wish to support our work with a Donation.

Focused Articles For You

Lay Portal